Affimed
Affimed Therapeutics is a publicly traded (Nasdaq: AFMD) clinical-stage biopharmaceutical company headquartered in Heidelberg, Germany, developing recombinant bispecific antibodies for cancer and other diseases, with 51-100 employees and a pipeline targeting BCMA-directed therapies in immuno-oncology.
- Company typePrivate
- Founded2000
- HeadquartersHeidelberg, Germany
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Affimed does
Affimed Therapeutics is a clinical-stage biopharmaceutical company headquartered in Heidelberg, Germany, and publicly listed on Nasdaq under the ticker AFMD. Founded in 2000, the company focuses on developing recombinant antibody therapeutics for the treatment of cancer and other diseases, operating specifically in the immuno-oncology and bispecific antibody segment of the biopharmaceutical market. With a workforce of 51-100 employees, Affimed pursues indications including BCMA-directed therapies, targeting a market projected to grow from $15.09 billion in 2025 to $44.29 billion by 2030 at roughly 24% CAGR.
The company's core technology centers on the engineering of bispecific antibodies designed to engage immune cells against tumor targets. Its product development operates within a small, specialized R&D footprint and relies on both equity financings and non-dilutive grant funding (e.g., German Federal Ministry of Research, Technology and Space) to advance pipeline candidates. Affimed has secured notable validation from major industry and financial investors, including a $96 million Roche-led round in 2018 and subsequent financings of $115 million in 2021 and $90 million in 2022.
Affimed's business model is consistent with pre-commercial biotech: revenue, where present, derives primarily from collaboration milestones, licensing, and grants rather than product sales. The company has not disclosed a commercial pricing model or marketed product in the available source data. Capital is sourced through public markets (Nasdaq listing) and a syndicate of specialized healthcare investors (OrbiMed, Novo Holdings, EQT Life Sciences, Aeris Capital, BioMedPartners, Perceptive Advisors), as well as strategic industry partners (Roche). Persistent net losses confirm ongoing cash burn typical of clinical development prior to commercial launch, and the absence of revenue mechanics disclosure limits visibility into a near-term commercial trajectory.
Affimed firmographics
Firmographics- Name
- Affimed
- Website
- https://affimed.com
- Company type
- Private
- Founded year
- 2000
- Headcount range
- 51–100 employees
- Short description
- Affimed Therapeutics is a publicly traded (Nasdaq: AFMD) clinical-stage biopharmaceutical company headquartered in Heidelberg, Germany, developing recombinant bispecific antibodies for cancer and other diseases, with 51-100 employees and a pipeline targeting BCMA-directed therapies in immuno-oncology.
- Ownership category
- akta.pro rank
Affimed industry classification
Industry- Product category
- Bispecific Antibody Therapeutics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Bispecific & Multispecific Antibodies (HLAAAAAF)
- akta.pro secondary industry
- Monoclonal Antibody Therapeutics (mAbs) (HLAAAAAA)
Keywords
Where Affimed is headquartered
LocationHeadquarters
- HQ city
- Heidelberg
- HQ country
- Germany
- HQ region
- Europe
Markets served
Affimed business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Others
Affimed product offering
Product offeringCore offering
Affimed Therapeutics develops recombinant antibody therapeutics, principally bispecific antibodies, for the treatment of cancer and other diseases. Its lead candidates engage immune effector cells (such as natural killer cells and T cells) to recognize and kill tumor cells. The company pursues both hematologic and solid tumor indications through its proprietary Immune Cell Engager (ICE) platform.
Differentiator
Problem solved
Functional benefit
Products and services
- Bispecific Antibody Therapeutics Pipeline
Companies that use Affimed
Customer profileIdeal customer profiles2 records
Affimed technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Affimed partnerships and signals
Strategic signalScale indicators1 record
Recent moves6 records
Expansion highlights4 records
Affimed competitors and assessment
Company assessmentDirect peers
- Compass Therapeutics: Clinical-stage biotech developing bispecific antibodies that engage NK cells against tumors, directly comparable to Affimed's ICE platform in both mechanism and stage of development.
- Genmab: Pioneer in bispecific antibody technology (DuoBody platform) and a leading direct competitor in the bispecific antibody space, with approved and clinical-stage oncology assets that compete directly with Affimed's recombinant bispecific pipeline.
- Zymeworks: Develops bispecific and multifunctional antibodies using its Azymetric and other platforms, making it a direct modality peer to Affimed in engineered antibody therapeutics for oncology.
- Xencor: Develops engineered bispecific antibodies using its XmAb platform for oncology and autoimmune indications, competing in the same bispecific antibody modality and partnership-driven business model as Affimed.
- Innate Pharma: Focused on NK cell-based immuno-oncology, including engagers and antibodies that mobilize innate immunity against tumors — a directly overlapping scientific approach with Affimed's innate cell engager (ICE) platform.
- MacroGenics: Clinical-stage biotech developing bispecific antibodies and antibody-based therapeutics for cancer, with overlapping oncology targets and a comparable development-stage profile to Affimed.
Broad incumbents
- Roche: Global pharmaceutical incumbent with a large bispecific antibody franchise and the historical strategic investor in Affimed (led $96M round in 2018); competes broadly with Affimed's oncology pipeline while also being a potential acquirer or partner.
- Regeneron: Large biopharmaceutical company with approved bispecific antibodies (e.g., Linvoseltamab, Odronextamab) in oncology, representing a well-capitalized incumbent competitor in the same therapeutic space as Affimed.
Emerging players
- CytomX Therapeutics: Clinical-stage biotech using Probody platform to create masked/conditional bispecific antibodies, partially overlapping with Affimed's bispecific antibody approach but differentiated by its tumor-microenvironment-activation strategy.
- GT Biopharma: Early clinical-stage biotech developing NK cell engagers and tri-specific antibodies for cancer, with a mechanism that directly mirrors Affimed's NK-cell-engager approach but at an earlier stage.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
Affimed social profiles
Digital presenceAffimed financial estimates
Financial estimateRevenue estimate
Valuation estimate
Affimed leadership team
Management profileNumber of profiles
Profiles8 records
Affimed funding detail
Funding detailFunding overview
Funding rounds14 records
Investors13 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Affimed M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Affimed
What does Affimed do?
Affimed Therapeutics develops recombinant antibody therapeutics, principally bispecific antibodies, for the treatment of cancer and other diseases. Its lead candidates engage immune effector cells (such as natural killer cells and T cells) to recognize and kill tumor cells. The company pursues both hematologic and solid tumor indications through its proprietary Immune Cell Engager (ICE) platform.
When was Affimed founded?
Affimed was founded in 2000. It employs 51 to 100 people.
Where is Affimed based?
Affimed is headquartered in Heidelberg, Germany, in the Europe region.
Who are Affimed's main competitors?
Direct peers on record are Compass Therapeutics, Genmab, Zymeworks, Xencor, Innate Pharma and MacroGenics. Broad incumbents are Roche and Regeneron. Emerging players are CytomX Therapeutics and GT Biopharma.
Does Affimed have an API?
No public API is recorded for Affimed.
What industry is Affimed in?
Affimed's product category is Bispecific Antibody Therapeutics. Its primary akta.pro industry code is HLAAAAAF, Bispecific & Multispecific Antibodies, with a secondary code of HLAAAAAA, Monoclonal Antibody Therapeutics (mAbs). Its NAICS code is 325414 and its SIC code is 2836.